Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C16G2 Gel for Dental Caries
NCT02254993Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Antimicrobial Peptides, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of C16G2 in dental caries (11 arms), sponsored by Armata Pharmaceuticals. Primary endpoint: Safety of single and multiple C16G2 Gel administrations. Started Oct 2014; status: completed.
02
Drugs
C16G2
03
Conditions
dental caries
Beyond the preview
Go deeper on NCT02254993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254993.